

11 β -Hydroxysteroid dehydrogenase type 1 contributes to the balance between 7-keto- and 7-hydroxy-oxysterols in vivo

Mitić, Tijana; Shave, Steven; Semjonous, Nina; Mcnae, Iain; Cobice, Diego F.; Lavery, Gareth G.; Webster, Scott P.; Hadoke, Patrick W.f.; Walker, Brian R.; Andrew, Ruth

DOI:

[10.1016/j.bcp.2013.02.002](https://doi.org/10.1016/j.bcp.2013.02.002)

License:

Creative Commons: Attribution (CC BY)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Mitić, T, Shave, S, Semjonous, N, Mcnae, I, Cobice, DF, Lavery, GG, Webster, SP, Hadoke, PWF, Walker, BR & Andrew, R 2013, '11 β -Hydroxysteroid dehydrogenase type 1 contributes to the balance between 7-keto- and 7-hydroxy-oxysterols *in vivo*', *Biochemical Pharmacology*, vol. 86, no. 1, pp. 146-153.
<https://doi.org/10.1016/j.bcp.2013.02.002>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Eligibility for repository : checked 6/08/2014

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.



11 β -Hydroxysteroid dehydrogenase type 1 contributes to the balance between 7-keto- and 7-hydroxy-oxysterols *in vivo*

Tijana Mitić^a, Steven Shave^b, Nina Semjonous^c, Iain McNae^b, Diego F. Cobice^a, Gareth G. Lavery^c, Scott P. Webster^a, Patrick W.F. Hadoke^a, Brian R. Walker^a, Ruth Andrew^{a,*}

^a Endocrinology, University/British Heart Foundation Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, Edinburgh, EH16 4TJ, UK

^b Institute of Structural and Molecular Biology, King's Buildings, University of Edinburgh, Edinburgh, EH9 3JR, UK

^c Centre for Endocrinology, Diabetes and Metabolism, School of Clinical & Experimental Medicine, University of Birmingham, Birmingham, B15 2TT, UK

ARTICLE INFO

Article history:

Received 18 December 2012

Accepted 4 February 2013

Available online 13 February 2013

Keywords:

7-Oxysterols

7 β -Hydroxycholesterol

7-Ketocholesterol

Glucocorticoids

11 β -Hydroxysteroid dehydrogenase 1

Corticosterone

ABSTRACT

11 β -Hydroxysteroid dehydrogenase 1 (11 β HSD1; EC 1.1.1.146) generates active glucocorticoids from inert 11-keto metabolites. However, it can also metabolize alternative substrates, including 7 β -hydroxy- and 7-keto-cholesterol (7 β OHC, 7KC). This has been demonstrated *in vitro* but its consequences *in vivo* are uncertain. We used genetically modified mice to investigate the contribution of 11 β HSD1 to the balance of circulating levels of 7KC and 7 β OHC *in vivo*, and dissected *in vitro* the kinetics of the interactions between oxysterols and glucocorticoids for metabolism by the mouse enzyme.

Circulating levels of 7KC and 7 β OHC in mice were 91.3 ± 22.3 and 22.6 ± 5.7 nM respectively, increasing to 1240 ± 220 and 406 ± 39 nM in *ApoE*^{−/−} mice receiving atherogenic western diet. Disruption of 11 β HSD1 in mice increased ($p < 0.05$) the 7KC/7 β OHC ratio in plasma (by 20%) and also in isolated microsomes (2 fold). The 7KC/7 β OHC ratio was similarly increased when NADPH generation was restricted by disruption of hexose-6-phosphate dehydrogenase.

Reduction and oxidation of 7-oxysterols by murine 11 β HSD1 proceeded more slowly and substrate affinity was lower than for glucocorticoids. *in vitro* 7 β OHC was a competitive inhibitor of oxidation of corticosterone ($K_i = 0.9$ μ M), whereas 7KC only weakly inhibited reduction of 11-dehydrocorticosterone. However, supplementation of 7-oxysterols in cultured cells, secondary to cholesterol loading, preferentially slowed reduction of glucocorticoids, rather than oxidation.

Thus, in mouse, 11 β HSD1 influenced the abundance and balance of circulating and tissue levels of 7 β OHC and 7KC, promoting reduction of 7KC. In health, 7-oxysterols are unlikely to regulate glucocorticoid metabolism. However, in hyperlipidaemia, 7-oxysterols may inhibit glucocorticoid metabolism and modulate signaling through corticosteroid receptors.

© 2013 Elsevier Inc. All rights reserved.

1. Introduction

Intracellular generation of active glucocorticoids (cortisol in humans, corticosterone in mice) is catalyzed by 11 β -hydroxysteroid dehydrogenase (11 β HSD) type 1 (EC 1.1.1.146). The potential for 11 β HSD1 to regulate fuel metabolism has been demonstrated in murine models, in which disruption of the enzyme protects from metabolic dyshomeostasis [1,2] and, more recently, in humans in

whom specific 11 β HSD1 inhibitors improve hyperglycaemia [3]. In murine models, inhibition of 11 β HSD1 also offers atheroprotection [4–6]. Therefore inhibition of the reductase activity of 11 β HSD1 is a tractable target for drug development, but to fully understand the spectrum of actions and side-effects of such drugs, effects on other substrates of 11 β HSD1 must be considered. This is, as yet, unexplored *in vivo*, either in genetically modified mice or following selective pharmacological manipulation.

In addition to metabolizing glucocorticoids, 11 β HSD1 can catalyze the inter-conversion of 7-keto- and 7 β -hydroxy-sterols and steroids (Fig. 1a) (e.g. 7-oxygenated metabolites of dehydroepiandrosterone [7] and highly cytotoxic cholesterol metabolites, the 7-oxysterols [8,9]). 7-Oxysterols are formed from cholesterol both enzymatically and by auto-oxidation [10]. They accumulate in atherosclerotic plaques, a site of 11 β HSD1 expression [11], with 7-ketocholesterol (7KC) being the most abundant, closely followed

* Corresponding author. Tel.: +44 131 242 6763; fax: +44 131 242 6779.

E-mail addresses: Tijana.mitic@bristol.ac.uk (T. Mitić), s.shave@ed.ac.uk

(S. Shave), nina_sem@hotmail.com (N. Semjonous), Iain.McNae@ed.ac.uk

(I. McNae), d.f.cobice@sms.ed.ac.uk (D.F. Cobice), g.g.lavery@bham.ac.uk

(G.G. Lavery), scott.webster@ed.ac.uk (S.P. Webster), patrick.hadoke@ed.ac.uk

(Patrick W.F. Hadoke), b.walker@ed.ac.uk (B.R. Walker), r.andrew@ed.ac.uk

(R. Andrew).




Fig. 1. (a) Interconversion of glucocorticoids and 7-oxysterols catalyzed by 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1). The equilibrium of interconversion of inert 11-keto and active 11β-hydroxy forms of glucocorticoids (shown here as 11-dehydrocorticosterone and corticosterone, the principle rodent glucocorticoids) favors predominant reduction. 11βHSD1 can also interconvert 7-keto and 7β-hydroxycholesterol but the favored equilibrium position between the two reactions is not understood. (b)–(e) *In Silico* modeling of interactions between 7-oxysterols and residues in the active site of murine 11β-hydroxysteroid dehydrogenase 1 (m11βHSD1). 2D Modeling of the active site of m11βHSD1 (retrieved from PDB 1Y5 M) using LigPlot. Hydrogen bond lengths of interactions between (b) 7-ketocholesterol and (c) 7β-hydroxycholesterol and the critical residues of catalytic tetrad are shorter than those for (d) 7α-hydroxycholesterol (7αOHC). (e) 3D modeling of interactions between active site residues Serine 170 (S170) and Tyrosine 183 (Y183) of m11βHSD1 and the 7-oxygenated moieties using PyMOL. Positioning of 7βOHC (pink) or 7KC (yellow) into the active site demonstrated their more favorable orientation over 7αOHC (turquoise), for hydrogen bonding with key amino acids of m11βHSD1 active site.

by 7β-hydroxycholesterol (7βOHC) [12]. Early reports [13,14] revealed that 11βHSD1 converted 7βOHC to 7KC in hepatic microsomes from all vertebrates tested (human, guinea-pig, rat, hamster and chicken) and that rat hepatic 11βHSD1 also reduced 7KC to 7βOHC. However, this has not been studied in other species and it remains unclear whether enzymes other than 11βHSD1 also catalyze interconversion of 7βOHC and 7KC.

11βHSD1 is a bi-directional enzyme (Fig. 1a) and both dehydrogenase (inactivating glucocorticoids) and reductase

(regenerating glucocorticoids) activities can be measured in tissues [15,16]. The prevalent direction of 11βHSD1, with respect to metabolism of glucocorticoids, is reduction and is dependent on the availability of endogenous co-factor (NADPH), which is generated by hexose-6-phosphate dehydrogenase (H6PDH) within the endoplasmic reticulum (ER) [17]. Mice lacking H6PDH are unable to regenerate glucocorticoids by 11βHSD1 [18] but it is unclear if NADPH supply physiologically regulates the balance between reductase and dehydrogenase activities and the contribution of H6PDH *in vivo* has not been investigated for 7-oxysterols. Pharmacological inhibition of 11βHSD1 in rats caused hepatic accumulation of 7KC [9] suggesting that, as with glucocorticoids, the predominant direction of metabolism of 7-oxysterols by 11βHSD1 *in vivo* is reduction. Tissue-specific differences in the equilibrium position of metabolism of glucocorticoids by 11βHSD1 may indeed be due to the presence of competitive substrates, as some reports have suggested that 7-oxygenated compounds inhibit metabolism of glucocorticoids by 11βHSD1 [19]. For example, 7KC and 7βOHC inhibit 11βHSD1 activity in mouse adipocyte (3T3-L1 and 3T3-F442) cell lines [20] and in differentiated human THP-1 macrophages [21], modulating the downstream actions of glucocorticoids.

We hypothesized that 11βHSD1 is a key determinant of the balance of 7βOHC and 7KC *in vivo*. Depending on their levels in the circulation and tissues, 7KC and 7βOHC may differentially inhibit either reduction or dehydrogenation of glucocorticoids, respectively. Since these oxysterols accumulate in tissues that express 11βHSD1 [10] (e.g. macrophages, foam cells, adipose, atherosclerotic plaques [11]), the relative proportion of 7KC to 7βOHC may influence the amount of active glucocorticoid within cells. To address this hypothesis we investigated the balance of 7KC and 7βOHC in mice with transgenic disruption of 11βHSD1 and H6PDH, and abilities of these 7-oxysterols to influence the equilibrium between the dehydrogenase and reductase activities of glucocorticoid metabolism by murine 11βHSD1.

2. Materials and methods

Unless otherwise stated, solvents were HPLC grade (Fisher, Hemel Hempstead, UK) and contained an anti-oxidant (0.01%w/v butylated hydroxytoluene (BHT)). Steroids and oxysterols were from Steraloids (Newport, Rhode Island, USA), derivatization reagents from Fluka (Buchs, Switzerland), tissue culture reagents from Lonza (Reading, UK) and other chemicals from Sigma–Aldrich (Poole, UK). Tritiated 11-dehydrocorticosterone (11-DHC) was synthesized [22] from [1,2,6,7-³H]₄-corticosterone (GE Healthcare, Bucks, UK). Deuterium-labeled internal standards [25,26,26,26,27,27,27-²H]₇-7KC, [25,26,26,26,27,27,27-²H]₇-7βOHC and [25,26,26,26,27,27,27-²H]₇-cholesterol were from CDN Isotopes (Essex, UK). Protein concentrations were quantified using a Bio-Rad kit (Hemel Hempstead, UK).

2.1. Animals

Male mice (10–16 weeks, *n* = 6–8/group [2,23]) with disruption of 11βHSD1 (*Hsd11b1*^{−/−}) or H6PDH (*H6pdh*^{−/−}) or both (*Hsd11b1*^{−/−}/*H6pdh*^{−/−}) and their wild-type littermate controls (15 weeks) were maintained on chow diet and tap water *ad libitum*, under a 16 h/8 h light/dark cycle at 21–24 °C. Male *ApoE*^{−/−} mice (in-house colony, 8 weeks; *n* = 6) were maintained on a western Diet (D12079B, Research Diets, USA) for 14 weeks. All licensed procedures were performed under accepted standards of humane animal care, as outlined in the UK Home Office Ethical Guidelines. Animals were culled by cervical dislocation at 10:00 h. Tissues and fluids were snap-frozen and stored at −80 °C.

2.2. Cell culture

HEK293 cells stably expressing full-length murine 11 β HSD1 (m11 β HSD1) [24] were maintained in Dulbecco's Modified Eagle Medium (DMEM) and seeded on poly-D-lysine coated (50 μ g/mL, 5 min) plates. Medium was supplemented with glutamine (2 mM), penicillin (100 units/mL), streptomycin (100 μ g/mL), and heat-inactivated fetal calf serum (10%v/v). For assessment of kinetic parameters, stripped fetal calf serum, prepared with dextran-coated charcoal (1% w/v), was added to the cells 12 h prior to use. For manipulation of cholesterol, medium was replaced with serum free medium 1 h prior to experimentation. Cells were maintained in a humidified atmosphere (5%CO₂, 95% air, 37 °C).

2.3. Quantitation of 11 β HSD1 enzyme kinetics

Inter-conversion of substrates and products was quantified under conditions of first order kinetics. Three forms of murine enzyme ($n=6$ /group) were used: (1) a truncated form of recombinant m11 β HSD1 protein (N23 Δ , gift from Dr Webster), (2) enzyme contained within murine hepatic microsomes and (3) a full-length m11 β HSD1 protein expressed in stably transfected HEK293 cells [24].

2.3.1. Metabolism by purified and microsomal murine 11 β HSD1

Recombinant (14–28 μ g/mL) or murine hepatic microsomal (240–260 μ g/mL [19]) protein was incubated (30 min, 37 °C) with 7-oxysterols (0.02–20 μ M) in potassium phosphate buffer (0.1 M, 0.1 mM EDTA, 20 mM cysteamine hydrochloride, pH 7.4), or with steroids (0.02–20 μ M) in Krebs-Ringer buffer (containing 5 mM glucose), and the relevant cofactor (2 mM) for oxidation (NADP⁺ or NAD⁺) or reduction (NADPH or NADH). Similar experiments were performed in hepatic microsomes from *Hsd11b1*^{−/−} mice [2] (substrate 0.2 μ M) with and without induction of cationic permeability by alameticine (0.25 mM, 1–2 h). Reactions did not proceed in the absence of either protein or the co-factor.

Following incubation, internal standards (epi-cortisol for steroids or 19-hydroxycholesterol (19OHC, 100 ng) and 4 α -cholesten-7 α -ol-3-one (50 ng) for oxysterols) were added after stopping the reaction with addition of ethyl acetate (steroids; 10 vol) or petroleum ether (oxysterols; 10 vol). Organic extracts were reduced to dryness under oxygen free nitrogen (60 °C) or argon (room temperature), respectively, and the residues stored at −20 °C until analysis by HPLC.

2.3.2. Metabolism by recombinant murine 11 β HSD1 expressed in stably transfected cells

HEK293 cells, stably transfected to produce m11 β HSD1, were seeded onto a 5 cm dish and incubated overnight with 7KC, 7 β OHC or 7 α OHC (1 μ M), or with steroid (30 nM) for 45 min. Following addition of internal standard, as above, oxysterols were extracted from the medium into 2-propanol:hexane (40:60, 9 mL, 50 μ g/mL BHT) [25]. Dried organic residues were stored at −20 °C until analysis by gas chromatography mass spectrometry (GCMS). Reactions did not proceed in non-transfected HEK293 cells.

2.4. Competition between 7-oxysterols and glucocorticoids for metabolism by 11 β HSD1

Recombinant protein (20 μ g/mL) was incubated, as above, in the presence of 11-DHC (0.5–10 μ M) or corticosterone (0.025–0.2 μ M) and 7KC (0.02–20 μ M) or 7 β OHC (0.02–10 μ M). Murine hepatic microsomes (260 μ g/mL) were incubated, as above, with steroid (0.2 μ M) in the presence of 7 β OHC or 7KC (0.1 nM–5 μ M).

The velocity of metabolism of steroids (0.02–5 μ M) was further assessed in the presence of 7-oxysterols at their IC₅₀ concentration (vehicle, 0.01% v/v ethanol). HEK293 cells expressing m11 β HSD1 were cultured, as above, and incubated with [³H]₄-labeled (5 nM) and unlabelled (25 nM) steroid and 7 β OHC or 7KC or other oxysterols (7 α -, 19-, 22R- or 27-OHC; 1 nM–5 μ M, 0.01% v/v ethanol control).

2.5. Supplementation of cholesterol in stably transfected cells

To enrich cellular cholesterol and 7-oxysterol content, HEK293 cells stably expressing m11 β HSD1 were incubated (37 °C, 30 min) with cholesterol-loaded methyl- β -cyclodextrin (1:6, 10 mM in DMEM) [26]) and kinetic experiments performed within 24 h. Following manipulation, cells were washed with DMEM (37 °C) followed by phosphate buffered saline, and then incubated (5×10^6 cells/well, 1 h) in serum-free DMEM containing either [³H]₄-corticosterone or [³H]₄-dehydrocorticosterone (30 nM). Products of metabolism were quantified in medium by HPLC. Following incubation, cells were washed with ice-cold PBS and then lysed by gently rocking with NaOH (200 μ M, 0.6 mL/well, 15 min, 4 °C) [27]. An aliquot of lysate was retained for quantitation of protein. To the remaining cellular lysate, internal standards [²H]₇-7KC, [²H]₇-7 β OHC (50 ng) and [²H]₇-cholesterol (1 μ g) were added and oxysterols and cholesterol were immediately extracted into methanol:hexane (2:5, 7 mL, 50 μ g/mL BHT, 2 mM EDTA). The dried organic extract was dissolved in chloroform: methanol (2:1) and processed for quantitation by GCMS. All final measurements were expressed as a ratio of the total protein content in the cells.

2.6. Quantitation of circulating and tissue levels of 7-oxysterols

7-Oxysterols were quantified in plasma (0.4–1 mL) prepared from trunk blood collected (pooled if necessary) in EDTA-coated tubes from mice ($n=8$ /group). Plasma was prepared from blood collected in EDTA-coated (1.6 mg/mL) vials. The effects of disruption of *Hsd1b1*, *H6pdh* or both were explored in hepatic microsomes and cytosol (0.05–0.5 mg/mL protein) from mice homozygous for the disrupted allele ($n=6$ /group) versus their littermate controls. All samples were flushed under argon prior to extraction and BHT (45 mM, in ethanol) added before 7-oxysterols were extracted and converted to their trimethylsilyl derivatives [28] prior to analysis by GCMS [29].

2.7. Quantitation of steroids and oxysterols by HPLC

Substrates and products in *in vitro* extracts were analyzed by HPLC (Dionex SUMMIT[®] system, Camberley UK) with online radiosintillation detection (LB509[®] β -scintillation counter, Berthold Technologies GmbH & Co, Germany). 7-Oxysterols were eluted from a SUNFIRE[®] column (C18, 15 cm, 4.6 mm, 5 μ m; Waters, Edinburgh, UK) with acetonitrile:water (95:5), at 1 mL/min, 24 °C and quantified at selected wavelengths (195 nm (7KC, 4 α -cholesten-7 α -ol-3-one), 237 nm (hydroxy-cholesterols)). Glucocorticoids were separated using a SYMMETRY[®] C8 column maintained at 35 °C (15 cm, 4.6 mm, 5 μ m, Waters) using a mobile phase of water:acetonitrile:methanol (60:15:25) flowing at 1 mL/min. Unlabelled steroids were detected at 240 nm. Unlabelled oxysterols and steroids were quantified by interpolation onto a standard curve of peak area divided by that of the internal standard vs concentration, prepared from calibration standards processed simultaneously. Abundances of tritiated steroids were quantified by on-line liquid scintillation counting (2 mL/min; GOLDFLOW[®], Meridian, Surrey, UK).

2.8. In silico modeling of interactions between 7-oxysterols and residues in the active site of murine 11 β -hydroxysteroid dehydrogenase 1 (m11 β HSD1)

3D Macromolecular structural information about m11 β HSD1 was obtained from the Research Laboratory for Structural Bioinformatics Protein Data Bank. 1Y5 M represented a dimeric m11 β HSD1 bound with NADP⁺ and 1Y5 R represented m11 β HSD1 bound with NADP⁺ and corticosterone [30]. The structure of 7 α -hydroxysteroid dehydrogenase (EC1.1.1.159, 7 α HSD, PDBID 1FMC) in complex with 7-oxoglycochenodeoxycholic acid [31] was a template for modeling the steric orientation of 7 α OHC, allowing alignment of 7 α - and 7 β -hydroxyl and 7-keto groups into the active site, when 7 α HSD and 11 β HSD1 were subsequently superimposed. Energy maps for all ligand atoms around the active site were generated using the virtual screening program LIDAEUS (Ligand Discovery At Edinburgh University). Energy minimization routines were used to aid the positioning of substrate within the active site of 11 β HSD1. 2D Representations of protein-ligand complexes from modeled structures were created using LigPlot (Cambridge, UK), the output of which was then augmented by 2D representations of substrates generated by MARVINVIEW[®] (ChemAxon, Budapest, Hungary) to distinguish between the steric orientation of 7 α - and 7 β OHC. Visualization of 3D structures was performed using PyMOL (open source, DeLano Scientific LLC).

2.9. Analysis of kinetics and statistics

V_{\max} , K_m and K_i values were determined, using global nonlinear regression, from data generated by measuring reaction velocity across a range of substrate concentrations in the absence and presence of competitor. In addition, using recombinant protein, Dixon Plots were generated as the reciprocal of the reaction velocity using four substrate concentrations [S] against four inhibitor concentrations [I]. All data are presented as mean \pm SEM. SEM. Non-linear regression and statistical comparisons were made using GRAPHPAD PRISM[®] software v5.0 (GraphPad Software Inc. San Diego, USA) by 1 or 2-way ANOVA (with Tukey post hoc tests), or unpaired or paired Student's *t*-tests as appropriate.

3. Results

3.1. Disruption of 11 β HSD1 or H6PDH in vivo impairs reduction of 7-oxysterols

7-Oxysterols were present in plasma from wild-type, littermate control mice in concentrations of 91.3 \pm 22.3 (7KC) and 22.6 \pm 5.7 (7 β OHC) nM [29]. Levels increased more than 10 fold (1240 \pm 22 (7KC) and 406 \pm 39 (7 β OHC) nM) in *ApoE*^{-/-} mice on an atherogenic, western diet. Following disruption of *Hsd11b1*, there was a trend ($p = 0.08$) for an increase in concentrations of 7KC (133.8 \pm 16.8 nM) but not 7 β OHC (23.6 \pm 2.2 nM) [29]. However, the ratio of

7KC/7 β OHC in plasma significantly increased in the *Hsd11b1*^{-/-} (5.4 \pm 0.5) vs. control mice (4.1 \pm 0.4, $n = 9$, $p < 0.05$).

Both 7KC and 7 β OHC were detected in microsomes from control mice. Disruption of *Hsd11b1* caused a profound reduction in hepatic microsomal concentrations of both oxysterols (Table 1), with an increase in the 7KC/7 β OHC ratio. In the cytosols from control murine liver, only 7KC (25.3 \pm 13.4 ng/mg protein) was detected, but following disruption of 11 β HSD1, levels of 7KC became undetectable. Disruption of *H6pdh*, or both *H6pdh* and *Hsd11b1* also lowered the levels of 7 β OHC and 7KC in the hepatic microsomes compared with littermate controls (Table 1). The 7KC/7 β OHC ratio increased with disruption of *H6pdh* and disruption of both *H6pdh* and *Hsd11b1* did not have any further effect over lack of 11 β HSD1 alone (Table 1).

3.1.1. Oxysterols Inhibit oxidation and/or reduction of glucocorticoids

Competition between 7-oxysterols and glucocorticoids for metabolism by 11 β HSD1 across physiological and pathophysiological concentration ranges was investigated using three preparations of murine enzyme. In all preparations, 7 α OHC was not accepted as a substrate and not generated upon reduction of 7KC (not shown).

3.1.2. Murine 11 β HSD1 stably transfected into HEK293 cells

Both oxidation and reduction of glucocorticoids were detected *in vitro*, and reduction was the preferred direction (0.79 \pm 0.15 (oxidation) vs. 3.86 \pm 0.27 (reduction) pmol/mg/min, respectively, with 30 nM substrate). Both oxidation of 7 β OHC and reduction of 7KC, were observed, at similar velocities, which were considerably slower than those measured for glucocorticoids. For example, substrate concentrations of 1 μ M were required to achieve rates of oxidation of 7 β OHC and reduction of 7KC of 0.90 \pm 0.31 vs 0.74 \pm 0.04 pmol/mg/min, respectively. Inhibition of metabolism of glucocorticoids by a range of endogenous oxysterols was assessed in both reductase and dehydrogenase directions. 7KC caused the most marked inhibition of reduction of all oxysterols tested, although still only by 40% at the highest concentration used (100 μ M; Fig. 2a) and further kinetic analysis was not performed. Of the different oxysterols tested, only 7 β OHC inhibited oxidation of corticosterone, with a K_i of 1.77 \pm 0.09 μ M (Fig. 2b).

3.1.3. Murine recombinant 11 β HSD1

Although both oxidation and reduction of glucocorticoids were detected using recombinant 11 β HSD1, reduction of 11-DHC was the favored reaction (lower K_m and higher V_{\max} ; Table 2). Oxidation of 7 β OHC and reduction of 7KC were also detected but proceeded with slower maximal rates and these substrates had poorer affinity (higher K_m s; Table 2) than glucocorticoids. 7KC inhibited reduction of 11-DHC (Fig. 2c) with a K_i of 7.33 \pm 1.76 μ M, and 7 β OHC inhibited dehydrogenation of corticosterone with a K_i of 0.91 \pm 0.05 μ M. (Fig. 2d). In both cases, the nature of inhibition was competitive, indicated by the regression lines of the Dixon Plots intercepting above the x-axis.

Table 1

Effect of disruption of *Hsd11b1* or *H6pdh* on 7-oxysterol concentrations in hepatic microsomes.

	Control	<i>Hsd11b1</i> ^{-/-}	<i>H6pdh</i> ^{-/-}	<i>Hsd11b1</i> ^{-/-} / <i>H6pdh</i> ^{-/-}
7 β OHC	84.45 \pm 27.55	16.10 \pm 5.20**	12.12 \pm 2.34**	21.44 \pm 3.50*.*
7KC	22.45 \pm 8.20	10.01 \pm 2.85*	7.78 \pm 1.68*	14.76 \pm 2.64*.*
7KC/7 β OHC	0.31 \pm 0.14	0.65 \pm 0.04*	0.63 \pm 0.01*	0.68 \pm 0.04**

Disruption of either 11 β -hydroxysteroid dehydrogenase 1 (*Hsd11b1*^{-/-}) or hexose-6-phosphate dehydrogenase (*H6pdh*^{-/-}) reduced levels (ng/mg protein) of 7 β -hydroxycholesterol (7 β OHC) to a greater extent than 7-ketocholesterol (7KC) in hepatic microsomes compared with littermate control (C57BL/6) mice. Disruption of both enzymes (*Hsd11b1*^{-/-}, *H6pdh*^{-/-}) did not have any additional effect on the levels of 7-oxysterols over lack of 11 β HSD1 or H6PDH alone. Data are mean \pm SEM, compared using 1-way ANOVA, and Tukey's post hoc test, $n = 4-6$.

* $p < 0.05$.

** $p < 0.01$ vs. control.

$p < 0.05$ compared with *H6pdh*^{-/-}.




Fig. 2. 7-Oxysterols inhibit the metabolism of glucocorticoids by 11β-hydroxysteroid dehydrogenase 1 (11βHSD1). (a) and (b): The velocities of (a) reduction of 11-dehydrocorticosterone (11-DHC) to corticosterone and (b) oxidation of corticosterone to 11-DHC were quantified following incubation of HEK293 cells (stably transfected to generate murine 11βHSD1) with a range of concentrations of oxysterols. Non-linear regression was used to assign IC₅₀ values. 7-Ketocholesterol (7KC) only inhibited the reduction of 11-DHC by ~40%. 7β-Hydroxycholesterol (7βOHC) completely inhibited oxidation of corticosterone; other oxysterols did not have an effect. Data (mean ± SEM) are % control (absence of oxysterol), *n* = 6 for 7-oxysterols and *n* = 3 for other oxysterols. OHC = hydroxycholesterol. (c)–(f) 7-Oxysterols inhibited metabolism of glucocorticoids by recombinant and microsomal 11βHSD1; in both cases they inhibited dehydrogenation more potently than reduction. Competitive inhibition of (c) reduction of 11-DHC to corticosterone in the presence of 7KC and (d) oxidation of corticosterone to 11-DHC in the presence of 7βOHC, by recombinant 11βHSD1, demonstrated by Dixon Plots (mean data). Inhibition of (e) reduction of 11-DHC to corticosterone in the presence of 7KC and (f) oxidation of corticosterone to 11-DHC in the presence of 7βOHC by microsomal 11βHSD1. *n* = 3–7. (g) Supplementation of cholesterol impeded reduction of glucocorticoids by 11βHSD1. The velocity of reduction of 11-DHC (open bars) by 11βHSD1 stably transfected in HEK293 was suppressed when 7-oxysterol levels were supplemented by delivery of a

3.1.4. 11βHSD1 in murine hepatic microsomes

Both oxidation and reduction of glucocorticoids were detected using microsomal 11βHSD1 with reduction being the preferred direction (lower *K_m* and higher *V_{max}*, Table 2). In contrast, only oxidation of 7βOHC could be measured, forming 7KC at the same rate in the presence of either NAD⁺ or NADP⁺ (e.g. 1.25 ± 0.2 vs. 1.35 ± 0.4 pmol/μg/min respectively; 20 μM substrate, *n* = 3). This reaction was dependent on the presence of 11βHSD1, as 7βOHC was not converted to 7KC by hepatic microsomes from *Hsd11b1*^{-/-} mice, with either cofactor. Again, 7-oxysterols demonstrated poorer affinity than glucocorticoids for 11βHSD1. The *K_m* for oxidation of 7βOHC was approximately three orders of magnitude higher than that for glucocorticoids (Table 2), although the maximal velocities achieved were similar for glucocorticoids and 7-oxysterols. Reduction of 7KC could not be demonstrated, even following the addition of the permeabilisation agent, alameticine, or use of NADH as an alternative cofactor [32]. 7KC weakly inhibited reduction of 11-DHC with an IC₅₀ of 19.4 ± 1.2 μM (Fig. 2e) and further kinetic analysis was not performed. 7βOHC inhibited oxidation with an IC₅₀ of 2.2 ± 0.4 μM (Fig. 2f).

3.2. Supplementation of cellular content of cholesterol and 7-oxysterol impedes reduction of glucocorticoids by 11βHSD1

The effect of cholesterol loading was assessed on the equilibrium of 11βHSD1 stably transfected into HEK293 cells. 7KC (19.4 ± 1.08 pmol/mg) and 7βOHC (4.37 ± 1.90 pmol/mg) were present in cells treated with vehicle. Cholesterol loading significantly (*p* < 0.05) increased the levels of 7KC (39.48 ± 3.01 pmol/mg) and 7βOHC (17.6 ± 2.4 pmol/mg), associated with a slower velocity of reduction of glucocorticoids by 11βHSD1 compared with vehicle-treated cells (Fig. 2g).

3.3. In silico modeling

3.3.1. 2D modeling

A representation of m11βHSD1 (PDB structure 1Y5R) was created to predict proximity of interactions of steroids and 7-oxysterols with resident cofactor (NADP⁺/NADPH) and the tyrosine (Tyr183) and serine (Ser170) residues of the catalytic tetrad (Tyr183-Ser170-Lys187-Asn143) (Figs. 1(b)–(d)) [33]. Distances of hydrogen bonds from the active C7 oxygen on 7-oxysterols to Ser170 and Tyr183 residues were shortest for 7βOHC (2.7, 2.8 Å respectively), longer for 7KC (3.2, 3.3 Å) and longest for 7αOHC (4.5, 3.5 Å). Distances of 7βOHC and 7KC were comparable to those of glucocorticoids (B, 3.0, 3.2; A, 2.8, 2.6 Å respectively). Interactions with the co-factor were similar for all three 7-oxysterols (all 3.0 Å; corticosterone 3.9, 11-DHC, 3.3 Å).

3.3.2. 3D in silico modeling

7-Oxysterols have not been co-crystallised with 11βHSD1. Thus, to establish the spatial orientation of the oxygenated residues at the C7 position, the structure of the closely related 7αHSD in complex with 7-oxoglycochenodeoxycholic acid (1FMC) was used. Tyrosine residues in the active sites of 7αHSD (1FMC) and m11βHSD1 (1Y5R) could be superimposed, allowing the 7α-hydroxyl group of 1FMC ligand to overlay the 11β-hydroxyl group of corticosterone docked within 1Y5R. Thus, the 3D structure of 7αOHC was created to resemble that of 7-oxoglycochenodeoxycholic acid, allowing the positions of the 7β-hydroxyl and 7-keto groups of 7βOHC and 7KC respectively to be orientated. 7-Oxysterols were docked into the active site of 1Y5R and 3D representations shown in Fig. 1e. The A-ring of 7-oxysterols (as opposed to the D-ring of glucocorticoids) was orientated toward

complex of cholesterol and methyl-β-cyclodextrin (1:6). **p* < 0.01 compared by 2 way ANOVA with Bonferroni post-test, *n* = 6.

Table 2Kinetic parameters describing metabolism of 7-oxysterols and glucocorticoids by murine 11 β -hydroxysteroid dehydrogenase 1 (11 β HSD1).

Substrate		K_m (μ M)	V_{max}	V_{max}/K_m
Recombinant protein				
11-Dehydrocorticosterone	Reduction	0.20 \pm 0.25	8.56 \pm 4.06	42.8
7-Ketocholesterol	Reduction	1 269 \pm 282	0.12 \pm 0.03	9 \times 10 ⁻⁵
Corticosterone	Oxidation	1.78 \pm 0.56	4.82 \pm 0.65	2.7
7 β -hydroxycholesterol	Oxidation	327.60 \pm 98.50	0.010 \pm 0.001	3 \times 10 ⁻⁵
Microsomes				
11-Dehydrocorticosterone	Reduction	1.30 \pm 0.54	1.19 \pm 0.18	0.9
7-Ketocholesterol	Reduction		Product not detected	
Corticosterone	Oxidation	4.20 \pm 2.01	0.04 \pm 0.01	0.01
7 β -hydroxycholesterol	Oxidation	3 500 \pm 326	0.03 \pm 0.001	9 \times 10 ⁻⁶

Velocities of metabolism of substrates by murine recombinant or microsomal 11 β HSD1 were assessed and kinetic parameters (K_m , V_{max} and V_{max}/K_m , true or apparent) assigned following Lineweaver–Burke transformation of data fitted to Michaelis–Menten kinetics. The velocities were quantified; for reduction of 11-dehydrocorticosterone or 7-ketocholesterol in the presence of NADPH or oxidation of corticosterone or 7 β -hydroxycholesterol in the presence of NADP⁺. Data are mean \pm SEM, obtained from at least three independent experiments. V_{max} expressed as pmol/ μ g/min. V_{max}/K_m expressed as L/ μ g/min \times 10⁻⁶.

the interior of the 11 β HSD1 active site. Interactions between 7 β OHC and Ser170 and Tyr183 of the catalytic tetrad had the shortest bond distances (2.7, 2.8 Å respectively), followed by those of 7KC (3.2, 3.3 Å) and then 7 α OHC (4.5, 4.8 Å; for comparison corticosterone 3.1, 2.8 Å [30]; 11-DHC 2.8, 2.6 Å respectively). When 7 β OHC and 7KC were docked, the Tyr183 residue was 5.1 Å from the nicotinamide C4 and Lys187 was 3.2 Å from the hydroxyl group on the cofactor. When 7 α OHC was docked, the Tyr183 residue was 4.20 Å from the nicotinamide C4 and Lys187 was 3.2 Å from the hydroxyl group on the cofactor.

4. Discussion

These data demonstrate that reduction of 7KC to 7 β OHC is the preferred direction of metabolism of 7-oxysterols by 11 β HSD1 *in vivo* in mouse. Metabolism of 7-oxysterols (at least dehydrogenation) was not detected in microsomes of 11 β HSD1 null mice, supporting the notion that it is the only enzyme catalyzing this reaction. While 7-oxysterols were competitive inhibitors of metabolism of glucocorticoids by 11 β HSD1, it is unlikely that in health [34] they will be sufficiently potent to exert this effect. Inhibition may become important in hyperlipidaemia [10], or at sites where oxysterols accumulate, such as in adipose and atherosclerotic lesions.

Structural modeling of the murine protein confirmed the potential for interactions of 7-oxysterols with the catalytic tetrad of the enzymatic active site. 7-Oxygenated substrates, in contrast to steroids, interact with 11 β HSD1 with their A-ring orientated toward the interior of the binding pocket, in agreement with models in other species [21,30,35]. The higher K_m values describing metabolism of 7-oxysterols compared with glucocorticoids, however, indicated they were poorer affinity substrates. Circulating concentrations of 7-oxysterols in the mouse were comparable in magnitude to those in other species [34] and increased in hyperlipidaemia [10]. However, it is likely metabolism by 11 β HSD1 would not proceed at maximal velocity in the presence of the endogenous concentrations reported here or by others [34,36].

While disruption of 11 β HSD1 only tended to alter circulating 7-oxysterol levels subtly [29], it substantially lowered the levels in hepatic sub-cellular fractions. Oxysterols can be synthesized from spontaneous oxidation of cholesterol and are derived in large part from dietary sources [10]. Therefore the reduction in absolute levels may arise because *Hsd11b1*^{-/-} mice have an improved metabolic profile with lower circulating cholesterol concentrations [37], and thus less precursor for auto-oxidation. The specific contribution of 11 β HSD1 to the proportions of 7-keto and hydroxy oxysterols was revealed in the increase in the ratio of 7KC/7 β OHC ratio in plasma and microsomes, following targeted disruption of *Hsd11b1*, suggesting that 11 β HSD1 catalyses reduction of 7KC *in*

vivo. This corroborates previous studies in rats in which hepatic 7KC accumulated following administration of the non-specific 11 β HSD inhibitor carbenoxolone [9]. Lack of NADPH supply due to genetic disruption of *H6pdh* again increased the 7KC/7 β OHC ratio, confirming *in vitro* findings [38] that H6PDH promotes catalysis of 7KC to form 7 β OHC *in vivo*, similarly to glucocorticoids. Indeed, H6PDH appeared to be the only source of co-factor, as double knockout of *H6pdh* and *Hsd11b1*, yielded the same ratio of 7-oxysterols, as with disruption of *H6pdh* alone.

11 β HSD1 may therefore play a similar role in regulating actions of 7-oxysterols *in vivo* as it does glucocorticoids. The importance of metabolism of glucocorticoids by 11 β HSD1 is readily apparent since the 11-keto steroid is inert and the hydroxy form is active. However, distinct biological roles for 7KC and 7 β OHC are not established and a target receptor has not been defined, although there are a number of reports of subtle differences in their actions (e.g. 7 β OHC has a greater ability than 7KC to induce apoptosis in human umbilical vein endothelial cells [39]). However 7-oxysterols can be subject to further metabolism and recent reports suggest that the 25- and 27-hydroxy metabolites of 7 α - and 7 β OHC play potential roles in regulating the immune response via the novel G-protein coupled receptor, EB12 [40,41]. Interestingly there is one report showing that 7KC but not 7 β OHC limits SCAP exit from the ER within cells [42], which further prevents excess synthesis of cholesterol. Hence, it follows that the increased proportion of 7KC to 7 β OHC upon inhibition of 11 β HSD1 *in vivo* may exert a brake on cholesterol synthesis. Other oxysterols modulate nuclear hormone signaling pathways, but the possibility of activation of LXR, at least, by 7-oxysterols has largely dismissed [20].

Work with cells stably transfected to express human 11 β HSD1 or with adipocytes [20] has shown that 7-oxysterols (in keeping with other 7-hydroxylated substrates [7]) may compete differentially with glucocorticoids for metabolism by 11 β HSD1 and thus modulate glucocorticoid action. Inhibition appears cell-type specific, potentially explained by differential metabolism, accumulation or export of oxysterols [10]; adipocytes and macrophages sequester oxysterols readily [10] whereas macrophages export 7KC and other oxysterols via the ABCG1 transporter [43]. Balázs et al. did not detect any inhibition of human 11 β HSD1 reductase activity in lysates or HEK293 cells by 7KC or 7 β OHC, but showed an inhibition of 11 β HSD1-reductase activity by 7KC (IC₅₀ 8.1 \pm 0.9 μ M) in differentiated THP-1 macrophages [21]. Inhibition of glucocorticoid metabolism by co-incubation with 7-oxysterols was investigated here using three models of murine 11 β HSD1, in all of which reduction of glucocorticoids was favored. Our data concur with the proposal that 7-oxysterols compete with glucocorticoids for metabolism, with 7KC being consistently less effective at inhibiting 11-DHC reduction by isolated enzyme *in vitro*, than 7 β OHC was at preventing oxidation. Taking into account the IC₅₀ values, inhibition

of glucocorticoid metabolism is unlikely to be important in health. However, at concentrations in the low micromolar range, as seen in atherosclerosis [44,45], 7 β OH or 7KC may compete for oxidation preventing glucocorticoid inactivation or reduction, respectively.

7 β OH is highly abundant in fatty streaks in developing lesions [46,47] and the 7 β OH/7KC ratio is increased. If 7 β OH dominates to inhibit glucocorticoid oxidation, the cells in the lesion and adjacent normal intima may become exposed to increased local glucocorticoid levels, with adverse consequences [48]. However, when endogenous 7-oxysterols were enriched secondary to cholesterol loading in cultured cells, the predominant effect was to suppress reduction of glucocorticoids, suggesting protection from excess glucocorticoid. These findings concur with reduction of 7KC being the major route of metabolism of 7-oxysterols *in vivo*.

In conclusion, 7KC and 7 β OH are poor affinity substrates for murine 11 β HSD1 and are interconverted at a slower rate than glucocorticoids. While differences exist in the patterns of *in vitro* and *in vivo* metabolism, reduction of 7KC to 7 β OH appears the predominant reaction *in vivo*. Although it seems unlikely that the competition with oxysterols will determine predominant direction for glucocorticoid metabolism by 11 β HSD1 in health, it may play a role in hyperlipidaemia and atherosclerosis. A greater knowledge of the actions of these 7-oxysterols is required to fully understand the consequences of inhibition or over-activity of 11 β HSD1 pathway.

Acknowledgements

We are grateful to the Wellcome Trust Clinical Research Facility Mass Spectrometry Core (Mrs Alison Rutter) for technical assistance. This work was supported by grants from the Wellcome Trust (TM, RA, PWFH, SP, BRW), British Heart Foundation (RA, DC, PWFH, BW) and Medical Research Council David Philips fellowship (GGL, NS).

References

- [1] Kotelevtsev YV, Holmes MC, Burchell A, Houston PM, Scholl D, Jamieson PM, et al. 11 β -Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid inducible responses and resist hyperglycaemia on obesity and stress. *Proc Natl Acad Sci U S A* 1997;94:14924–29.
- [2] Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 β -hydroxysteroid dehydrogenase type 1-deficient mice. *Diabetes* 2004;53:931–8.
- [3] Rosenstock J, Banarar S, Fonseca VA, Inzucchi SE, Sun W, Yao W, et al. The 11 β -hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with Type 2 diabetes inadequately controlled by metformin monotherapy. *Diabetes Care* 2010;33:1516–22.
- [4] Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, et al. 11 β -HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. *J Exp Med* 2005;202:517–27.
- [5] Kipari T, Hadoke PWF, Iqbal J, Man TY, Miller E, Coutinho AE. 11 β -hydroxysteroid dehydrogenase type 1 deficiency reduces atherosclerosis and plaque inflammation independent of risk factors: key role of the lesional environment. *FASEB Journal*; <http://dx.doi.org/10.1096/fj.12-219105>, in press.
- [6] Luo MJ, Thieringer R, Springer MS, Wright SD, Hermanowski-Vosatka A, Plump A, et al. 11 β -HSD1 inhibition reduces atherosclerosis in mice by altering pro-inflammatory gene expression in the vasculature. *Physiol Genomics* 2013;45:47–57.
- [7] Robinson B, Michael KK, Ripp SL, Winters sj, Prough RA glucocorticoids inhibit interconversion of 7-hydroxy and 7-oxo metabolites of dehydroepiandrosterone: a role for 11 β -hydroxysteroid dehydrogenases? *Arch Biochem Biophys* 2003;412:251–8.
- [8] Hult M, Elleby B, Shafqat N, Svensson S, Rane A, Jorvall H, et al. Human and rodent type 1 11 β -hydroxysteroid dehydrogenases are 7 β -hydroxycholesterol dehydrogenases involved in oxysterol metabolism. *Cell Mol Life Sci* 2004;61:992–9.
- [9] Schweizer RA, Zurcher M, Balazs Z, Dick B, Odermatt A. Rapid hepatic metabolism of 7-ketocholesterol by 11 β -hydroxysteroid dehydrogenase type 1: species-specific differences between the rat human, and hamster enzyme. *J Biol Chem* 2004;279:18425–34.
- [10] Brown AJ, Jessup W. Oxysterols Sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis. *Mol Aspects Med* 2009;30:111–22.
- [11] Morton NM. Obesity and corticosteroids: 11 β -hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. *Mol Cell Endocrinol* 2010;316:154–64.
- [12] Brown AJ, Leong SL, Dean RT, Jessup W. 7-Hydroperoxycholesterol and its products in oxidized low density lipoprotein and human atherosclerotic plaque. *J Lipid Res* 1997;38:1730–45.
- [13] Song W, Chen J, Dean WL, Redinger RN, Prough RA. Purification and characterization of hamster liver microsomal 7 α -hydroxycholesterol dehydrogenase: similarity to type I 11 β -hydroxysteroid dehydrogenase. *J Biol Chem* 1998;273:16223–28.
- [14] Maeda Y, Nagatomo H, Uchiyama F, Yamada M, Shiotsuki H, Ohta Y, et al. A comparative study of the conversion of 7-hydroxycholesterol in rabbit, guinea pig, rat, hamster and chicken. *Steroids* 2002;67:703–8.
- [15] Bujalska IJ, Walker EA, Hewison M, Stewart PM. A switch in dehydrogenase to reductase activity of 11 β -hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. *J Clin Endocrinol Metab* 2002;87:1205–10.
- [16] Hughes KA, Manolopoulos KN, Iqbal J, Cruden NL, Stimson RH, Reynolds RM, et al. Recycling between cortisol and cortisone in human splanchnic, subcutaneous adipose and skeletal muscle tissues *in vivo*. *Diabetes* 2012;61:1357–64.
- [17] Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, et al. Mutations in the genes encoding 11 β -hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. *Nature Genet* 2003;34:434–9.
- [18] Lavery GG, Walker EA, Draper N, Jeyasuria P, Marcos J, Shackleton CHL, et al. Hexose-6-phosphate dehydrogenase knock-out mice lack 11 β -hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation. *J Biol Chem* 2006;281:6546–51.
- [19] McNeilly AD, MacFarlane DP, O'Flaherty EN, Livingstone DEW, MacKenzie SM, Mitic T, et al. Bile acids modulate glucocorticoid metabolism and the hypothalamic-pituitary-adrenal axis in obstructive jaundice. *J Hepatol* 2010;52:705–11.
- [20] Wamil M, Andrew R, Chapman KE, Street J, Morton NM, Seckl JR. 7-Oxysterols modulate glucocorticoid activity in adipocytes through competition for 11 β -hydroxysteroid dehydrogenase type 1. *Endocrinology* 2008;149:5909–18.
- [21] Balazs Z, Nashev LG, Chandsawangbhuwan C, Baker ME, Odermatt A. Hexose-6-phosphate dehydrogenase modulates the effect of inhibitors and alternative substrates of 11 β -hydroxysteroid dehydrogenase 1. *Mol Cell Endocrinol* 2009;301:117–22.
- [22] Brown RW, Chapman KE, Edwards CRW, Seckl JR. Human placental 11 β -hydroxysteroid dehydrogenase: evidence for and partial purification of a distinct NAD-dependent isoform. *Endocrinology* 1993;132:2614–21.
- [23] Semjonous NM, Sherlock M, Jeyasuria P, Parker KL, Walker EA, Stewart PM, et al. Hexose-6-phosphate dehydrogenase contributes to skeletal muscle homeostasis independent of 11 β -hydroxysteroid dehydrogenase type 1. *Endocrinology* 2011;152:93–102.
- [24] Webster SP, Ward P, Binnie M, Craigie E, McConnell KM, Sooy K, et al. Discovery and biological evaluation of adamantyl amide 11 β -HSD1 inhibitors. *Bioorg Med Chem Lett* 2007;17:2838–43.
- [25] Freeman NE, Rusinol AE, Linton M, Hachey DL, Fazio S, Sinensky MS, et al. Acyl-coenzyme A: cholesterol acyltransferase promotes oxidized LDL/oxysterol-induced apoptosis in macrophages. *J Lipid Res* 2005;46:1933–43.
- [26] Klein U, Gimpl G, Fahrenholz F. Iteration of the myometrial plasma membrane cholesterol content with β -cyclodextrin modulates the binding affinity of the oxytocin receptor. *Biochemistry* 1995;34:13784–93.
- [27] Kritharides L, Jessup W, Mander EL, Dean RT. Apolipoprotein A-I-mediated efflux of sterols from oxidized LDL-loaded macrophages. *Arterioscler Thromb Vasc Biol* 1995;15:276–89.
- [28] Dzeletovic S, Breuer O, Lund E, Diczfalusy U. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. *Anal Biochem* 1995;225:73–80.
- [29] Mitic T, Andrew R, Walker BR, Hadoke PWF. Inter-conversion of 7-ketocholesterol and 7 β -hydroxycholesterol by 11 β -HSD1 in the mouse aortic wall: implications for vascular function. *Biochimie* 2013;95:548e555.
- [30] Zhang J, Osslund TD, Plant MH, Clogston CI, Nybo RE, Xiong F, et al. Crystal structure of murine 11 β -hydroxysteroid dehydrogenase 1: an important therapeutic target for diabetes. *Biochemistry* 2005;44:6948–57.
- [31] Tanaka N, Nonaka T, Tanabe T, Yoshimoto T, Tsuru D, Mitsui Y. Crystal structures of the binary and ternary complexes of 7 α -hydroxycholesterol dehydrogenase from *Escherichia coli*. *Biochemistry* 1996;35:7715–30.
- [32] Christy C, Hadoke PWF, Paterson JM, Mullins JJ, Seckl JR, Walker BR. Glucocorticoid action in mouse aorta; localisation of 11 β -hydroxysteroid dehydrogenase type 2 and effects on responses to glucocorticoids *in vitro*. *Hypertension* 2003;42:580–7.
- [33] Filling C, Berndt KD, Benach J, Knapp S, Prozorovski T, Nordling E, et al. Critical residues for structure and catalysis in short-chain dehydrogenases/reductases. *J Biol Chem* 2002;277:25677–84.
- [34] Iuliano L, Michelatta F, Natoli S, Ginanni Corradini SIM, Elisei W, Giovannelli L, et al. Measurement of oxysterols and α -tocopherol in plasma and tissue samples as indices of oxidant stress status. *Anal Biochem* 2003;312:217–23.
- [35] Odermatt A, Atanasov AG, Balazs Z, Schweizer RA, Nashev LG, Schuster D, et al. Why is 11 β -hydroxysteroid dehydrogenase type 1 facing the endoplasmic reticulum lumen? Physiological relevance of the membrane topology of 11 β -HSD1. *Mol Cell Endocrinol* 2006;248:15–23.

- [36] Brown AJ, Jessup W. Oxysterols and atherosclerosis. *Atherosclerosis* 1999;142: 1–28.
- [37] Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ, et al. Improved lipid and lipoprotein profile, hepatic insulin sensitivity and glucose tolerance in 11 β -hydroxysteroid dehydrogenase 1 knockout mice. *J Biol Chem* 2001;276:41293–300.
- [38] Atanasov AG, Nashev LG, Schweizer RA, Frick C, Odermatt A. Hexose-6-phosphate dehydrogenase determines the reaction direction of 11 β -hydroxysteroid dehydrogenase type 1 as an oxoreductase. *FEBS Lett* 2004;571: 129–33.
- [39] Steffen Y, Wiswedel I, Peter D, Schewe T, Sies H. Cytotoxicity of myeloperoxidase/nitrite-oxidized low-density lipoprotein toward endothelial cells is due to a high 7 β -hydroxycholesterol to 7-ketocholesterol ratio. *Free Radic Biol Med* 2006;41:1139–50.
- [40] Liu C, Yang XV, Wu J, Kuei C, Mani NS, Zhang L, et al. Oxysterols direct B-cell migration through EBI2. *Nature* 2011;475:519–23.
- [41] Hannedouche S, Zhang J, Yi T, Shen W, Nguyen D, Pereira JP, et al. Oxysterols direct immune cell migration via EBI2. *Nature* 2011;475:524–7.
- [42] Brown AJ, Sun L, Feramisco JD, Brown MS, Goldstein JL. Cholesterol addition to ER membranes alters conformation of SCAP the SREBP escort protein that regulates cholesterol metabolism. *Mol Cell* 2002;10:237–45.
- [43] Terasaka N, Wang N, Yvan-Charvet L, Tall AR. High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1. *Proc Natl Acad Sci U S A* 2007;104:15093–98.
- [44] Hitsumoto T, Takahashi M, Lizuka T, Shirai K. Clinical significance of serum 7-ketocholesterol concentrations in the progression of coronary atherosclerosis. *J Atheroscler Thromb* 2009;16:363–70.
- [45] Prunet C, Petit JM, Ecarnot-Laubriet A, Athias A, Miguel-Alfonsi C, Rohmer JF, et al. High circulating levels of 7 β - and 7 α -hydroxycholesterol and presence of apoptotic and oxidative markers in arterial lesions of normocholesterolemic atherosclerotic patients undergoing endarterectomy. *Pathol Biol (Paris)* 2006;54:22–32.
- [46] Carpenter KL, Taylor SE, van der Veen C, Williamson BK. Lipids and oxidised lipids in human atherosclerotic lesions at different stages of development. *Biochim Biophys Acta* 1995;1256:141–50.
- [47] Garcia-Cruzet S, Carpenter KL, Guardiola F, Stein BK, Mitchinson MJ. Oxysterol profiles of normal human arteries fatty streaks and advanced lesions. *Free Radic Res* 2001;35:31–41.
- [48] Hadoke PWF, Macdonald LJ, Logie JJ, Small GR, Dover AR, Walker BR. Intravascular glucocorticoid metabolism as a modulator of vascular structure and function. *Cell Mol Life Sci* 2006;63:565–78.